NCT03610971 2026-01-29Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase InhibitorsH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Active not recruiting24 enrolled